Janet K Coller

Summary

Affiliation: University of Adelaide
Country: Australia

Publications

  1. pmc Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis
    Janet K Coller
    Discipline of Pharmacology, School of Medical Sciences
    Pharmgenomics Pers Med 2:9-19. 2009
  2. pmc Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients
    Janet K Coller
    Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, SA 5005, Australia
    Br J Clin Pharmacol 74:835-41. 2012
  3. doi request reprint OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence
    Janet K Coller
    Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, Australia
    Pharmacogenet Genomics 21:902-5. 2011
  4. doi request reprint Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence
    Janet K Coller
    Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, South Australia 5005, Australia
    Pharmacol Ther 134:219-45. 2012
  5. ncbi request reprint Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone
    J K Coller
    Discipline of Pharmacology, Medical School North, University of Adelaide, Australia
    Int J Clin Pharmacol Ther 45:410-7. 2007
  6. ncbi request reprint ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals
    Janet K Coller
    Discipline of Pharmacology, School of Medical Sciences, The University of Adelaide, and Department of Clinical Pharmacology, Royal Adelaide Hospital, SA, Australia
    Clin Pharmacol Ther 80:682-90. 2006
  7. pmc Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity
    Janet K Coller
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Auerbachstr 112, D 70376 Stuttgart, Germany
    Br J Clin Pharmacol 57:105-11. 2004
  8. ncbi request reprint Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies
    J K Coller
    Department of Clinical and Experimental Pharmacology, The University of Adelaide, Adelaide, South Australia, Australia
    Clin Exp Pharmacol Physiol 30:845-8. 2003
  9. doi request reprint Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies
    Benjamin D Noll
    Department of Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville Discipline of Pharmacology, The University of Adelaide, Adelaide Central Northern Adelaide Renal Transplant Service, The Royal Adelaide Hospital, Adelaide, Australia Departments of Internal Medicine and Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Ther Drug Monit 35:617-23. 2013
  10. pmc Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice
    Yue Wu
    Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, South Australia, Australia
    Br J Pharmacol 165:1319-29. 2012

Collaborators

Detail Information

Publications32

  1. pmc Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis
    Janet K Coller
    Discipline of Pharmacology, School of Medical Sciences
    Pharmgenomics Pers Med 2:9-19. 2009
    ..Nonetheless, despite no evidence of a direct association with risk of dependence, A118G may still influence the pharmacological response to opioids impacting on an individual's dosage requirements...
  2. pmc Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients
    Janet K Coller
    Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, SA 5005, Australia
    Br J Clin Pharmacol 74:835-41. 2012
    ....
  3. doi request reprint OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence
    Janet K Coller
    Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, Australia
    Pharmacogenet Genomics 21:902-5. 2011
    ..Therefore, while naltrexone was an effective treatment for alcohol dependence, the OPRM1 A118G genotype was not a predictor of success...
  4. doi request reprint Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence
    Janet K Coller
    Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, South Australia 5005, Australia
    Pharmacol Ther 134:219-45. 2012
    ....
  5. ncbi request reprint Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone
    J K Coller
    Discipline of Pharmacology, Medical School North, University of Adelaide, Australia
    Int J Clin Pharmacol Ther 45:410-7. 2007
    ..To investigate the influence of CYP2D6 genotype on the oral clearance of (R)-, (S)- and rac-methadone...
  6. ncbi request reprint ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals
    Janet K Coller
    Discipline of Pharmacology, School of Medical Sciences, The University of Adelaide, and Department of Clinical Pharmacology, Royal Adelaide Hospital, SA, Australia
    Clin Pharmacol Ther 80:682-90. 2006
    ..This retrospective study aimed to investigate the influence of ABCB1 genetic variability on methadone dose requirements...
  7. pmc Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity
    Janet K Coller
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Auerbachstr 112, D 70376 Stuttgart, Germany
    Br J Clin Pharmacol 57:105-11. 2004
    ..To characterize the interindividual variability and the individual CYP involved in the formation of alpha-hydroxy-, N-desmethyl- and N-didesmethyl-tamoxifen from tamoxifen...
  8. ncbi request reprint Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies
    J K Coller
    Department of Clinical and Experimental Pharmacology, The University of Adelaide, Adelaide, South Australia, Australia
    Clin Exp Pharmacol Physiol 30:845-8. 2003
    ..6. Genotyping of patients with regards to CYP2B6, CYP2C9 and CYP2D6 may play a role in prediction of Z-4-OH-tam formation and, consequently, ultimate therapeutic benefit of tamoxifen treatment...
  9. doi request reprint Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies
    Benjamin D Noll
    Department of Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville Discipline of Pharmacology, The University of Adelaide, Adelaide Central Northern Adelaide Renal Transplant Service, The Royal Adelaide Hospital, Adelaide, Australia Departments of Internal Medicine and Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Ther Drug Monit 35:617-23. 2013
    ..This study aimed to develop a method for the quantification of TAC in small biopsy-sized samples of rat kidney and liver tissue, which could be applied to clinical biopsy samples from kidney transplant recipients...
  10. pmc Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice
    Yue Wu
    Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, South Australia, Australia
    Br J Pharmacol 165:1319-29. 2012
    ..The aim of the current study was to determine whether TLR4-MyD88-dependent signalling is involved in the acute behavioural actions of alcohol and if alcohol can activate TLR4-downstream MAPK and NF-κB pathways...
  11. pmc The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver
    Janet K Coller
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Br J Clin Pharmacol 54:157-67. 2002
    ....
  12. doi request reprint The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro
    Yibai Li
    Discipline of Pharmacology, The University of Adelaide, South Australia, Australia
    Drug Metab Dispos 41:1264-72. 2013
    ..05). These results indicate a major role of CYP2B6 in ketamine N-demethylation in vitro and a significant impact of the CYP2B6*6 allele on enzyme-ketamine binding and catalytic activity...
  13. pmc Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: comparison of different mouse strains
    Liang Liu
    Discipline of Pharmacology, School of Medical Sciences, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia 5005, Australia
    Brain Behav Immun 25:1223-32. 2011
    ..Moreover, this study demonstrated the advantages of utilizing multiple mouse strains and indicates that appropriate choice of mouse strains could enhance future research outcomes...
  14. pmc The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia
    Benjamin J Davies
    Department of Cardiology and Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville, and Department of Clinical and Experimental Pharmacology, The University of Adelaide, South Australia
    Br J Clin Pharmacol 61:321-5. 2006
    ..This study has investigated the effect of the number of functional CYP2D6 alleles and the influence of CYP2D6*2 alleles on plasma perhexiline concentrations in patients administered a standard loading regimen over 3 days...
  15. ncbi request reprint Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments
    Daniel T Barratt
    Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia
    Am J Med Genet B Neuropsychiatr Genet 141:323-31. 2006
    ..This suggests the need for a further prospective investigation into the role of the DRD2 A(1) allele in heroin use and response to maintenance pharmacotherapies for opioid dependence...
  16. pmc Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects
    Eloise A Gelston
    Discipline of Pharmacology, School of Medical Sciences, Faculty of Health Sciences, University of Adelaide, Adelaide, Australia
    Br J Clin Pharmacol 73:786-94. 2012
    ..To compare the O-demethylation (CYP2D6-mediated), N-demethylation (CYP3A4-mediated) and 6-glucuronidation (UGT2B4/7-mediated) metabolism of codeine between methadone- and buprenorphine-maintained CYP2D6 extensive metabolizer subjects...
  17. doi request reprint Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence
    Liang Liu
    Discipline of Pharmacology, School of Medical Sciences, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia
    Pharmacogenet Genomics 19:869-76. 2009
    ..To confirm a previous study, we also examined the association between the IL-1B genetic polymorphism and alcohol dependence...
  18. pmc CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes
    Mark R Hutchinson
    Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide, Australia, 5005
    Br J Clin Pharmacol 57:287-97. 2004
    ....
  19. pmc Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline
    Benjamin J Davies
    Department of Cardiology and Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville, South Australia, Australia
    Br J Clin Pharmacol 65:347-54. 2008
    ....
  20. doi request reprint Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies
    Zaipul I Md Dom
    Department of Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia Discipline of Pharmacology, School of Medical Sciences, The University of Adelaide, Adelaide, SA 5005, Australia
    J Chromatogr B Analyt Technol Biomed Life Sci 945:171-7. 2014
    ..The method was successfully applied to the quantification of MPA in human kidney biopsies without the need to alter current clinical protocols. ..
  21. ncbi request reprint Pharmacogenetics of opioids
    Andrew A Somogyi
    Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, Australia
    Clin Pharmacol Ther 81:429-44. 2007
    ....
  22. ncbi request reprint Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography
    Benjamin J Davies
    Department of Cardiology and Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville 5011, South Australia
    J Chromatogr B Analyt Technol Biomed Life Sci 832:114-20. 2006
    ..The current study describes an enantioselective method that utilises pre-column formation of fluorescent diastereomers that are resolved on a C18 HPLC column using a gradient of methanol and water...
  23. ncbi request reprint Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography
    Benjamin J Davies
    Department of Cardiology and Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia
    J Chromatogr B Analyt Technol Biomed Life Sci 843:302-9. 2006
    ..D.) renal clearances of trans1-OH-PHX and cis-OH-PHX were 1.58+/-0.35 and 0.16+/-0.06l/h, respectively. The mean (+/-S.D.) dose recovered in urine as free and glucuronidated 4-monohydroxy PHX metabolites was 20.6+/-11.6%...
  24. ncbi request reprint Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4
    J K Coller
    Department of Clinical and Experimental Pharmacology, University of Adelaide, Australia
    Xenobiotica 29:973-86. 1999
    ..1-2.7 respectively. CYP2C19, CYP3A4 and CYP1A2 mediated the formation of both 3'-hydroxyflunitrazepam and desmethylflunitrazepam. Investigators need carefully to consider the choice of organic solvent to avoid false CYP identification...
  25. pmc Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline
    Benjamin J L Davies
    Department of Cardiology and Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville 5011, South Australia, Australia
    Br J Clin Pharmacol 57:456-63. 2004
    ..The aim of this study was to determine whether perhexiline produces clinically significant inhibition of CYP2D6-catalysed metabolism in angina patients...
  26. doi request reprint Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies--a method suitable for small (<1 mg) samples
    Benjamin D Noll
    Department of Clinical Pharmacology, Basil Hetzel Institute, The Queen Elizabeth Hospital, Woodville, SA, Australia
    Ther Drug Monit 33:688-93. 2011
    ....
  27. doi request reprint Role of active metabolites in the use of opioids
    Janet K Coller
    Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, 5005, Australia
    Eur J Clin Pharmacol 65:121-39. 2009
    ..Thus, dose individualisation and the avoidance of adverse effects of opioids due to the accumulation of active metabolites or lack of formation of active metabolites are important considerations when opioids are used...
  28. ncbi request reprint Pharmacogenomics of methadone maintenance treatment
    Andrew A Somogyi
    Discipline of Pharmacology, School of Medical Sciences, Faculty of Health Sciences, University of Adelaide, Adelaide 5005, Australia
    Pharmacogenomics 15:1007-27. 2014
    ....
  29. doi request reprint Attenuation of microglial and IL-1 signaling protects mice from acute alcohol-induced sedation and/or motor impairment
    Yue Wu
    Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, SA, Australia
    Brain Behav Immun 25:S155-64. 2011
    ..Collectively these data suggest that alcohol is capable of rapid modification of proinflammatory immune signaling in the brain and this contributes significantly to the pharmacology of alcohol...
  30. ncbi request reprint A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis
    H M James
    Institute of Medical and Veterinary Science, Adelaide, Australia
    Int J Clin Pharmacol Ther 42:719-23. 2004
    ..To establish a method suitable for diagnostic genotyping of CYP2D6 alleles by DNA sequencing...
  31. ncbi request reprint Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia
    Sally C Inglis
    Department of Cardiology and Clinical Pharmacology, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville, SA 5011, Australia
    Pharmacogenet Genomics 17:305-12. 2007
    ..This study investigated the effects of increasing doses of rac-perhexiline maleate and CYP2D6 phenotype and genotype on the pharmacokinetics of (+) and (-)-perhexiline...
  32. ncbi request reprint CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes
    Benjamin J Davies
    Department of Cardiology and Clinical Pharmacology, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville, SA 5011, Australia
    Drug Metab Dispos 35:128-38. 2007
    ..CYP2B6 and CYP3A4 are minor contributors to the intrinsic P450-mediated hepatic clearance of both enantiomers of PHX, except in CYP2D6 PMs...